SCTR K12 Mentored Career Development Program

Specialties: Movement Disorders, Neuromodulation, Neuroimaging

Sam J Crowley earned his doctorate degree in clinical and health psychology from the University of Florida. He completed his predoctoral internship at Emory University and his postdoctoral fellowship at the VA Ann Arbor/Michigan Medicine consortium. He provides neuropsychological evaluations for a variety of patients, with a focus on movement disorders. His research interests include biological and cognitive predictors of decline in Lewy body disease, as well as nonpharmacological interventions to improve cognitive function.

Dr. Jessica English is an adult rheumatologist with clinical and research interests in reproductive health in rheumatic diseases, with a focus on systemic lupus erythematosus. She is dedicated to providing comprehensive care to patients throughout their reproductive health journeys and to advancing research aimed at improving pregnancy outcomes in women with lupus.

Dr. English has received multiple research awards and has presented her work at national and international conferences. She is committed to medical education and teaches within the MUSC College of Medicine, including lectures for Internal Medicine residents. She also participates in community patient education events focused on lupus and reproductive health.

Dr. English earned her MD from East Tennessee State University Quillen College of Medicine and completed her internal medicine residency and adult rheumatology fellowship at MUSC. She served as chief resident in internal medicine and chief fellow in rheumatology and earned a Master of Science in Clinical Research with a focus on pregnancy outcomes in lupus.

I received my Ph.D. in Molecular Pharmacology from the University of Illinois College of Medicine in 2017. I then completed my postdoctoral training at the National Cancer Institute, before accepting a faculty position at MUSC. The RAS-MAPK pathway is hyperactivated in 30 to 40% of human cancers; however, there remains a dearth of effective drugs that target this pathway. The primary objective of our lab is to uncover new vulnerabilities in RAS-MAPK signaling through the study of rare disease-associated mutations therein.